4-Antibody appoints ceo and new board member
To develop more partnerships with corporate pharma
Burns has previously held senior positions in the antibody area as ceo of Oslo, Norway-based Affitech and Celldex Therapeutics in the US.
Max Burger, 4-Antibody’s chairman, said Burns is a deal-maker and has the experience to drive 4-Antibody forward to achieve additional multi-target collaborations with corporate pharma to add to the partnership recently put in place with Boehringer Ingelheim.
Von Rüden was formerly ceo at Direvo Industrial Biotechnology in Cologne, Germany. Prior to this, he was chairman of Direvo’s Advisory Board and worked as president and ceo at Direvo Biotech until Bayer Schering acquired the company in September 2008.
Von Rüden also spent six years as cso and executive VP of Business Development with MorphoSys in Munich. Before that he was director of Molecular Biology responsible for drug discovery in oncology at Boehringer Ingelheim in Vienna.
‘We expect Thomas’s knowledge of key trends in pharma antibody discovery and development to add incremental momentum to our pursuit of new corporate partnerships as well as our internal drug discovery and development programmes,’ said Burns.
You may also like
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development
Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures
A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Finance
Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach
The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position